Gyre Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Gyre Therapeutics
GYRE Stock   8.02  0.20  2.56%   
Gyre Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Gyre Therapeutics' valuation are provided below:
Gross Profit
102.4 M
Profit Margin
0.062
Market Capitalization
772.6 M
Enterprise Value Revenue
6.6537
Revenue
107.3 M
There are over one hundred nineteen available fundamental trends for Gyre Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Gyre Therapeutics' regular performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2.1 B. The current year's Enterprise Value is expected to grow to about 2.1 B

Gyre Therapeutics Total Revenue

127.7 Million

Check Gyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gyre Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 127.7 M, Gross Profit of 123 M or Other Operating Expenses of 59.9 M, as well as many indicators such as Price To Sales Ratio of 8.32, Dividend Yield of 0.17 or PTB Ratio of 19.45. Gyre financial statements analysis is a perfect complement when working with Gyre Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Gyre Stock
Check out the analysis of Gyre Therapeutics Correlation against competitors.
For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.

Gyre Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets120.4 M144.2 M108.4 M
Pretty Stable
Common Stock Shares Outstanding123.5 M117.6 M33.2 M
Slightly volatile
Liabilities And Stockholders Equity120.4 M144.2 M108.4 M
Pretty Stable
Other Stockholder Equity235.1 M156.6 M248.4 M
Pretty Stable
Short and Long Term Debt Total1.7 M1.8 M6.6 M
Slightly volatile
Non Current Liabilities Total6.4 M6.7 M6.9 M
Slightly volatile
Total Liabilities45 M24.3 M27.2 M
Pretty Stable
Other Current Liabilities19 M18.1 M8.8 M
Slightly volatile
Total Current Liabilities20.5 M17.6 M19.6 M
Pretty Stable
Property Plant And Equipment Net31 M29.6 M8.7 M
Slightly volatile
Accounts Payable118 K124.2 K1.8 M
Pretty Stable
Cash10.1 M10.6 M36.5 M
Slightly volatile
Non Current Assets Total73.2 M69.7 M22.4 M
Slightly volatile
Cash And Short Term Investments22.8 M24 M71.9 M
Slightly volatile
Net Receivables27.5 M26.2 M9 M
Slightly volatile
Other Current Assets2.5 M3 M2.6 M
Slightly volatile
Total Current Assets83.6 M58.3 M89.1 M
Slightly volatile
Short Term Debt779 K820 K6 M
Slightly volatile
Intangible Assets2.3 M2 M10.4 M
Very volatile
Common Stock103.8 K98.9 K38.8 K
Slightly volatile
Non Currrent Assets Other2.6 M2.7 M6.9 M
Slightly volatile
Capital Lease Obligations1.1 M1.8 M1.2 M
Very volatile
Property Plant And Equipment Gross29 M36 M23.5 M
Slightly volatile
Capital Stock73.5 K77.4 K6.8 M
Slightly volatile
Net Working Capital42.5 M52.1 M37 M
Slightly volatile
Non Current Liabilities Other6 K6.3 K46.1 K
Slightly volatile
Good Will1.2 M1.3 M1.5 M
Slightly volatile

Gyre Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue127.7 M121.6 M46.1 M
Slightly volatile
Other Operating Expenses59.9 M103 M65.1 M
Slightly volatile
Research Development13.1 M13.8 M29 M
Slightly volatile
Total Operating Expenses58.3 M98.6 M63 M
Slightly volatile
Cost Of Revenue5.3 M4.5 M6.8 M
Very volatile
Depreciation And Amortization765.9 K1.4 M831.6 K
Pretty Stable
Interest Expense613 K645.3 K5.3 M
Slightly volatile
Selling General Administrative13.8 M14.5 M347.6 M
Slightly volatile
Selling And Marketing Expenses49.2 M51.8 M379.7 M
Slightly volatile
Tax Provision6.9 M6.1 M6.2 M
Pretty Stable
Net Interest Income983.7 K1.8 M541.1 K
Slightly volatile
Interest Income1.6 M1.4 M883.9 K
Slightly volatile
Reconciled Depreciation1.2 M1.4 M1.7 M
Slightly volatile

Gyre Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow36.4 M30.2 M42 M
Slightly volatile
Depreciation765.9 K1.4 M831.6 K
Pretty Stable
Capital Expenditures3.8 M3.6 M1.7 M
Slightly volatile
End Period Cash Flow10.1 M10.6 M36.5 M
Slightly volatile
Stock Based Compensation710.5 K747.9 K57.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.328.7613.4 K
Very volatile
Dividend Yield0.170.15131.2811
Pretty Stable
Days Sales Outstanding11011665.3684
Slightly volatile
Book Value Per Share1.091.04672
Slightly volatile
Average Payables1.2 M1.4 M1.5 M
Slightly volatile
Stock Based Compensation To Revenue0.00860.00928.5665
Very volatile
Capex To Depreciation1.351.771.6881
Slightly volatile
EV To Sales8.248.6813.1 K
Very volatile
Payables Turnover33.9932.3714.0643
Slightly volatile
Sales General And Administrative To Revenue0.170.1817.0176
Slightly volatile
Average Inventory91.2 K108.2 K117.1 K
Slightly volatile
Research And Ddevelopement To Revenue0.09720.18.8344
Slightly volatile
Capex To Revenue0.02530.02663.8
Very volatile
Cash Per Share0.340.361.6 K
Slightly volatile
Days Payables Outstanding11.0911.67888
Very volatile
Intangibles To Total Assets0.01280.01220.0154
Slightly volatile
Current Ratio3.633.828.4304
Slightly volatile
Tangible Book Value Per Share1.071.02672
Slightly volatile
Receivables Turnover3.964.1736.4364
Slightly volatile
Graham Number1.681.7725.9719
Slightly volatile
Capex Per Share0.04020.042319.0917
Slightly volatile
Average Receivables3 M2.8 M2.9 M
Slightly volatile
Revenue Per Share1.361.4369.8942
Slightly volatile
Interest Debt Per Share0.02050.021656.7338
Slightly volatile
Debt To Assets0.01090.01150.1065
Slightly volatile
Days Of Payables Outstanding11.0911.67888
Very volatile
Ebt Per Ebit1.571.651.0771
Slightly volatile
Quick Ratio3.273.448.2069
Slightly volatile
Net Income Per E B T0.580.470.8393
Slightly volatile
Cash Ratio0.660.73.7288
Slightly volatile
Days Of Sales Outstanding11011665.3684
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.761.671.0947
Slightly volatile
Fixed Asset Turnover7.354.736.8486
Slightly volatile
Debt Ratio0.01090.01150.1065
Slightly volatile
Price Sales Ratio8.328.7613.4 K
Very volatile
Asset Turnover0.80.760.3529
Slightly volatile

Gyre Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 B1.2 B1.3 B
Very volatile
Enterprise Value2.1 B1.2 B1.2 B
Very volatile

Gyre Fundamental Market Drivers

Forward Price Earnings80
Cash And Short Term Investments26.7 M

Gyre Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Gyre Therapeutics Financial Statements

Gyre Therapeutics stakeholders use historical fundamental indicators, such as Gyre Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Gyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Gyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue140.4 K133.4 K
Total Revenue121.6 M127.7 M
Cost Of Revenue4.5 M5.3 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.18  0.17 
Research And Ddevelopement To Revenue 0.10  0.10 
Capex To Revenue 0.03  0.03 
Revenue Per Share 1.43  1.36 
Ebit Per Revenue 0.15  0.18 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:
How To Invest In Gyre
Details
Is Gyre Stock a good investment?
Details
What is Gyre Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Gyre Therapeutics Correlation against competitors.
For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could Gyre diversify its offerings? Factors like these will boost the valuation of Gyre Therapeutics. Market participants price Gyre higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Gyre Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.662
Earnings Share
0.04
Revenue Per Share
1.227
Quarterly Revenue Growth
0.199
Return On Assets
0.0528
Understanding Gyre Therapeutics requires distinguishing between market price and book value, where the latter reflects Gyre's accounting equity. The concept of intrinsic value - what Gyre Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Gyre Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Gyre Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY